针对SARS-CoV-2的第一种初级/加强疫苗类型对体液免疫反应具有长期影响

IF 4.5 3区医学 Q2 IMMUNOLOGY

Clinical immunology Pub Date : 2025-05-15 DOI:10.1016/j.clim.2025.110523

Franz Mai , Emil C. Reisinger , Brigitte Müller-Hilke

{"title":"针对SARS-CoV-2的第一种初级/加强疫苗类型对体液免疫反应具有长期影响","authors":"Franz Mai , Emil C. Reisinger , Brigitte Müller-Hilke","doi":"10.1016/j.clim.2025.110523","DOIUrl":null,"url":null,"abstract":"<div><div>The outbreak of COVID-19 spurred the development of different vaccines against SARS-CoV-2 however, recommendations on how to maintain long-term protection from COVID-19 remain elusive.</div><div>We here report on a cohort of 192 health care workers receiving their primary vaccination with either AZD1222 or BNT162b2. Over the course of three years, six blood samples were taken and analyzed for antibody dynamics against the receptor binding domain of the Spike protein and for function via surrogate virus neutralization.</div><div>Our results showed that higher anti SARS-CoV-2 S titers correlated with increased neutralizing capacity and ameliorated COVID-19 disease. The type of the first prime/boost vaccine exerted long term effects with a homologous BNT162b2 regimen outperforming AZD1222 in terms of antibody titers and neutralizing capacity. This deficit for AZD1222 was not compensated for by subsequent boosting with RNA vaccines, was still evident after three years, and is discussed in the context of immune imprinting.</div></div>","PeriodicalId":10392,"journal":{"name":"Clinical immunology","volume":"278 ","pages":"Article 110523"},"PeriodicalIF":4.5000,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The type of the first prime/boost vaccine against SARS-CoV-2 exerts long-term effects on the humoral immune response\",\"authors\":\"Franz Mai , Emil C. Reisinger , Brigitte Müller-Hilke\",\"doi\":\"10.1016/j.clim.2025.110523\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>The outbreak of COVID-19 spurred the development of different vaccines against SARS-CoV-2 however, recommendations on how to maintain long-term protection from COVID-19 remain elusive.</div><div>We here report on a cohort of 192 health care workers receiving their primary vaccination with either AZD1222 or BNT162b2. Over the course of three years, six blood samples were taken and analyzed for antibody dynamics against the receptor binding domain of the Spike protein and for function via surrogate virus neutralization.</div><div>Our results showed that higher anti SARS-CoV-2 S titers correlated with increased neutralizing capacity and ameliorated COVID-19 disease. The type of the first prime/boost vaccine exerted long term effects with a homologous BNT162b2 regimen outperforming AZD1222 in terms of antibody titers and neutralizing capacity. This deficit for AZD1222 was not compensated for by subsequent boosting with RNA vaccines, was still evident after three years, and is discussed in the context of immune imprinting.</div></div>\",\"PeriodicalId\":10392,\"journal\":{\"name\":\"Clinical immunology\",\"volume\":\"278 \",\"pages\":\"Article 110523\"},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2025-05-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical immunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1521661625000981\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical immunology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1521661625000981","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

COVID-19的爆发刺激了针对SARS-CoV-2的不同疫苗的开发，然而，关于如何保持对COVID-19的长期保护的建议仍然难以获得。我们在此报告了192名接受AZD1222或BNT162b2初级疫苗接种的卫生保健工作者的队列。在三年的时间里，采集了六份血液样本并分析了针对Spike蛋白受体结合域的抗体动力学以及通过替代病毒中和的功能。我们的研究结果表明，抗sars - cov - 2s滴度越高，中和能力越强，COVID-19疾病得到改善。第一种启动/加强疫苗具有长期效果，同源BNT162b2方案在抗体滴度和中和能力方面优于AZD1222。随后的RNA疫苗增强并没有弥补AZD1222的缺陷，在三年后仍然很明显，并且在免疫印迹的背景下进行了讨论。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The type of the first prime/boost vaccine against SARS-CoV-2 exerts long-term effects on the humoral immune response

The outbreak of COVID-19 spurred the development of different vaccines against SARS-CoV-2 however, recommendations on how to maintain long-term protection from COVID-19 remain elusive.

We here report on a cohort of 192 health care workers receiving their primary vaccination with either AZD1222 or BNT162b2. Over the course of three years, six blood samples were taken and analyzed for antibody dynamics against the receptor binding domain of the Spike protein and for function via surrogate virus neutralization.

Our results showed that higher anti SARS-CoV-2 S titers correlated with increased neutralizing capacity and ameliorated COVID-19 disease. The type of the first prime/boost vaccine exerted long term effects with a homologous BNT162b2 regimen outperforming AZD1222 in terms of antibody titers and neutralizing capacity. This deficit for AZD1222 was not compensated for by subsequent boosting with RNA vaccines, was still evident after three years, and is discussed in the context of immune imprinting.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical immunology 医学-免疫学

CiteScore

12.30

自引率

1.20%

发文量

212

审稿时长

34 days

期刊介绍： Clinical Immunology publishes original research delving into the molecular and cellular foundations of immunological diseases. Additionally, the journal includes reviews covering timely subjects in basic immunology, along with case reports and letters to the editor.